Freeman Spogli Institute for International Studies Program on Energy and Sustainable Development Stanford University


Photo of Jeremy Goldhaber-Fiebert

Jeremy Goldhaber-Fiebert, PhD   Download vCard
Assistant Professor of Medicine and CHP/PCOR Core Faculty Member

Stanford University School of Medicine
117 Encina Commons, Room 217
Stanford, CA 94305-6019
(650) 721-2486 (voice)
(650) 723-1919 (fax)

Research Interests
Decision science; International health policy; Cost-effectiveness analysis; Simulation modeling

+PDF+ Jeremy Goldhaber-Fiebert's Curriculum Vitae (128.5KB, modified September 2011)
+WEB+ Personal URL

Jeremy Goldhaber-Fiebert, PhD, is an Assistant Professor of Medicine, a Core Faculty Member at the Centers for Health Policy/Primary Care and Outcomes Research, and a Faculty Affiliate of the Stanford Center on Longevity and Stanford Center for International Development. His research focuses on complex policy decisions surrounding the prevention and management of increasingly common, chronic diseases and the life course impact of exposure to their risk factors. In the context of both developing and developed countries including the US, India, China, and South Africa, he has examined chronic conditions including type 2 diabetes and cardiovascular diseases, human papillomavirus and cervical cancer, tuberculosis, and hepatitis C and on risk factors including smoking, physical activity, obesity, malnutrition, and other diseases themselves. He combines simulation modeling methods and cost-effectiveness analyses with econometric approaches and behavioral economic studies to address these issues. Dr. Goldhaber-Fiebert graduated magna cum laude from Harvard College in 1997, with an A.B. in the History and Literature of America. After working as a software engineer and consultant, he conducted a year-long public health research program in Costa Rica with his wife in 2001. Winner of the Lee B. Lusted Prize for Outstanding Student Research from the Society for Medical Decision Making in 2006 and in 2008, he completed his PhD in Health Policy concentrating in Decision Science at Harvard University in 2008. He was elected as a Trustee of the Society for Medical Decision Making in 2011.

Past and current research topics:

  1. Type 2 diabetes and cardiovascular risk factors: Randomized and observational studies in Costa Rica examining the impact of community-based lifestyle interventions and the relationship of gender, risk factors, and care utilization.
  2. Cervical cancer: Model-based cost-effectiveness analyses and costing methods studies that examine policy issues relating to cervical cancer screening and human papillomavirus vaccination in countries including the United States, Brazil, India, Kenya, Peru, South Africa, Tanzania, and Thailand.
  3. Measles, haemophilus influenzae type b, and other childhood infectious diseases: Longitudinal regression analyses of country-level data from middle and upper income countries that examine the link between vaccination, sustained reductions in mortality, and evidence of herd immunity.
  4. Patient adherence: Studies in both developing and developed countries of the costs and effectiveness of measures to increase successful adherence. Adherence to cervical cancer screening as well as to disease management programs targeting depression and obesity is examined from both a decision-analytic and a behavioral economics perspective.
  5. Simulation modeling methods: Research examining model calibration and validation, the appropriate representation of uncertainty in projected outcomes, the use of models to examine plausible counterfactuals at the biological and epidemiological level, and the reflection of population and spatial heterogeneity.

Stanford Departments


The 5 most recent are displayed. More publications »

Events & Presentations

The 5 most recent are displayed. More events & presentations »

Research Programs & Projects

News around the web

Stanford scientists model hepatitis C treatment options
Using a computer model of the hepatitis C disease, Jeremy Goldhaber-Fiebert and his research team have shown that two new drugs intended to target the virus are cost-effective for patients suffering from advanced hepatitis C, despite some significant side effects.
February 28, 2012 in The Stanford Daily

Benefits of hepatitis C treatment outweigh costs for patients with advanced disease, study shows
Using a computer model of hepatitis C disease — which accounts for different treatments, outcomes, disease stages and genetics — a research team led by Jeremy Goldhaber-Fiebert, PhD, found that new triple-therapies for genotype-1 hepatitis C are cost-effective for patients with advanced disease. Their results were published Feb. 21 in the Annals of Internal Medicine.
February 21, 2012 in Scope (blog)

Health insurance exhibits no effects for diabetics in developing countries
According to a recent study, those with health insurance do not experience better care or treatment for diabetes than those without insurance in developing countries such as India and China. The study, which will be published on Jan. 24 in the journal of the American Diabetes Association titled Diabetes Care, ...
January 17, 2012 in The Stanford Daily

Food Summit encourages researchers to collaborate across disciplines
... and health outcomes researcher Jeremy Goldhaber-Fiebert. More than 350 members of the campus community attended the inaugural Stanford Food Summit Nov.
November 4, 2010 in Stanford University News

Stanford experts gather for 'Food Summit'
The recent research on obesity and malnutrition in India, led by Jeremy Goldhaber-Fiebert of the Woods Institute, is a classic example of food's ...
November 4, 2010 in The Stanford Daily

More news around the web »